Sequoia India Leads $6 Mn Funding Round In Cancer Diagnostics Startup OncoStem

Sequoia India Leads $6 Mn Funding Round In Cancer Diagnostics Startup OncoStem

SUMMARY

Cancer Diagnostics Startup OncoStem Will Use The Funds For Expansion In New Markets In Asia And Europe

OncoStem Diagnostics, an oncology-focused cancer diagnostics startup, has raised $6 Mn in a funding round led by Sequoia India. Existing investor Artiman Ventures also participated in the round. OncoStem is focused on personalised cancer treatment planning through the development of tests that predict the chance of recurrence in patients.

Earlier this month Sequoia also participated in the $30 Mn in Series C funding of Bengaluru-based genomics research and diagnostics company MedGenome. n June 2017, US-based venture capitalist Sequoia Capital raised $4 Bn funding, as per the latest SEC filings.

OncoStem will use the newly raised funds to deepen its R&D efforts, develop effective tests for oral, brain and colon cancer and automate these tests. Apart from this, the company will focus to expand its presence in India and introduce the test in new markets in Asia as well as Europe.

Anjana Sasidharan, Principal, Sequoia Capital India Advisors, said, “OncoStem is filling a critical need gap and helping spare thousands of patients from severe chemotherapy, the associated toxic effects and the costs. The technology and pricing can fundamentally change patient access to such cutting edge tests, which have been prohibitively expensive in most markets globally so far. Also, the biomarkers discovered through OncoStem’s predictive analysis of cancer recurrence will help pharma companies in developing new targeted drugs.”

Bengaluru-headquartered OncoStem Diagnostics was founded in 2011. Their lead product ‘CanAssist-Breast’, claims to help close to 50% of patients to avoid the severe side-effects of unnecessary chemotherapy. Patients can update their details and request a test report, after paying the fees on its website itself.

Manjiri Bakre, founder and CEO, OncoStem Diagnostics said, “Cancer treatment has been continuously evolving with new research and oncologists have realised that a one-size-fits-all approach to cancer patients is not conducive. However, there are no affordable tests in India to accurately predict the risk of cancer recurrence. We aim to develop innovative and cost-effective tests that will help predict and assess the risk of recurrence in cancer patients, thus providing doctors with an actionable blueprint for personalised treatments.”

OncoStem’s flagship product ‘CanAssist-Breast’, is a robust and cost-effective ‘Morphometric ImmunoHistoChemistry’ (mIHC) test. It can predict the risk of recurrence for HR+ breast cancer patients from Stage 1 up to Stage 3A. Currently, it is available in India, Sri Lanka and Bangladesh.

In addition to CanAssist-Breast, OncoStem will soon launch another test for patients suffering from Triple-Negative Breast Cancer (TNBC). While tumors of this category are generally aggressive in nature, not all patients have a high risk of recurrence and may not require severe and multiple rounds of chemotherapy to combat it. Currently there aren’t any concrete tests to determine the severity of TNBC. OncoStem claims that its new test, which will be introduced by the end of 2018, will assess the severity of the cancer and help in planning the appropriate treatment procedure for the patient.

As per a WHO, Cancer is a leading cause of death worldwide and accounted for 7.6 Mn deaths (around 13% of all deaths) in 2008. Deaths from cancer worldwide are projected to continue to rise to over 13.1 Mn in 2030. Presently in India, it is a major cause of morbidity and mortality. Many cancers are preventable by controlling the modifiable risk factors such as tobacco use, alcohol use, unhealthy diet and physical inactivity, amongst others. In addition, a significant proportion of cancers can be cured, by surgery, radiotherapy or chemotherapy, especially if they are detected early.

Other startups that are working in the oncology and cancer diagnostics space include Ratan Tata-backed cancer therapeutic startup, Invictus Oncology, Celon Labs, iGenetics Diagnostics, etc. With the recent round of funding from Sequoia Capital, oncology and cancer diagnostics firm OncoStem will focus on launching the new product as well as expansion into new markets in Southeast Asia.

You have reached your limit of free stories
Become An Inc42 Plus Member

Become a Startup Insider in 2024 with Inc42 Plus. Join our exclusive community of 10,000+ founders, investors & operators and stay ahead in India’s startup & business economy.

2 YEAR PLAN
₹19999
₹7999
₹333/Month
Unlock 60% OFF
Cancel Anytime
1 YEAR PLAN
₹9999
₹4999
₹416/Month
Unlock 50% OFF
Cancel Anytime
Already A Member?
Discover Startups & Business Models

Unleash your potential by exploring unlimited articles, trackers, and playbooks. Identify the hottest startup deals, supercharge your innovation projects, and stay updated with expert curation.

Sequoia India Leads $6 Mn Funding Round In Cancer Diagnostics Startup OncoStem-Inc42 Media
How-To’s on Starting & Scaling Up

Empower yourself with comprehensive playbooks, expert analysis, and invaluable insights. Learn to validate ideas, acquire customers, secure funding, and navigate the journey to startup success.

Sequoia India Leads $6 Mn Funding Round In Cancer Diagnostics Startup OncoStem-Inc42 Media
Identify Trends & New Markets

Access 75+ in-depth reports on frontier industries. Gain exclusive market intelligence, understand market landscapes, and decode emerging trends to make informed decisions.

Sequoia India Leads $6 Mn Funding Round In Cancer Diagnostics Startup OncoStem-Inc42 Media
Track & Decode the Investment Landscape

Stay ahead with startup and funding trackers. Analyse investment strategies, profile successful investors, and keep track of upcoming funds, accelerators, and more.

Sequoia India Leads $6 Mn Funding Round In Cancer Diagnostics Startup OncoStem-Inc42 Media
Sequoia India Leads $6 Mn Funding Round In Cancer Diagnostics Startup OncoStem-Inc42 Media
You’re in Good company